Business
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mOS of 64.8 months and a 5-year OS rate of 52.3%.Torpalimab plus chemotherapy has been approved in over 40 countries, representing the new standard of care for the 1st line treatment of R/M NPC.The final OS analysis of JUPITER-06 confirms the sustained survival benefit with toripalimab plus chemothera
About this update from Shanghai Junshi Biosciences Co., Ltd. Class A
[{"type":"image","alt":"Junshi Biosciences","displaySize":"","headline":null,"caption":"Junshi Biosciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":150,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/971d658a30455dfc9bd856efb4c84acc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4euD1KvxSTvPpofaq76LRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/971d658a30455dfc9bd856efb4c84acc","width":150,"height":56}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Long-term OS follow-up analysis of JUPITER-02 demonstrates significantly better and clinically meaningful improvement with toripalimab plus chemotherapy as 1st-line treatment for R/M NPC, achieving mOS of 64.8 months and a 5-year OS rate of 52.3%.","length":247,"tagName":"p"}]},{"val":[{"type":"text","content":"Torpalimab plus chemotherapy has been approved in over 40 countries, representing the new standard of care for the 1st line treatment of R/M NPC.","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"The final OS analysis of JUPITER-06 confirms the sustained survival benefit with toripalimab plus chemotherapy in advanced ESCC, showing a mOS of 17.7 months and a 3-year OS rate of 29.7%.","length":188,"tagName":"p"}]},{"val":[{"type":"text","content":"Results from JUPITER-02 and JUPITER-06 were orally presented at ESMO Asia 2025.","length":79,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":659,"olType":false},{"type":"text","content":"SHANGHAI, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced new and promising long-term survival results from JUPITER-02 (NCT03581786) and JUPITER-06 (NCT03829969) at the European Society for Medical Oncology (ESMO) ASIA Congress 2025. JUPITER-02 and JUPITER-06 evaluated toripalimab, an anti-PD-1 antibody developed by Junshi Biosciences, in combination with chemotherapy as first-line treatment for recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) in JUPITER-02 and advanced or metastatic esophageal squamous cell carcinoma (ESCC) in JUPITER-06.","length":774,"tagName":"p","attribs":{}},{"type":"text","...
More updates from Shanghai Junshi Biosciences Co., Ltd. Class A